Clinical profile of an unselected population with heart failure treated with vericiguat in real life: differences with the VICTORIA trial

Introduction Vericiguat, an oral stimulator of soluble guanylate cyclase, reduces cardiovascular mortality and hospitalisations in patients with heart failure (HF) and reduced ejection fraction, as demonstrated in the VICTORIA trial. This study assessed the real-world use of vericiguat.Material and...

ver descrição completa

Detalhes bibliográficos
Autores: Esteban-Fernández, A, Recio-Mayoral, A, López-Vilella, R, De Lara, G, Barrantes-Castillo, M, Gómez-Otero, I, Nuñez-Villota, J, Robles-Gamboa, C, López-Aguilera, J, Iniesta-Manjavacas, A, Fluvió, P, Pastor-Pérez, F, Belarte-Tornero, L, Alonso-Salinas, G, Díez-Villanueva, P, ERISEC Registry Researchers
Formato: artículo
Estado:Versión publicada
Fecha de publicación:2025
País:España
Recursos:Fundación para el Fomento de la Investigación Sanitaria y Biomédica de la Comunitat Valenciana (FISABIO)
Repositorio:r-FISABIO. Repositorio Institucional de Producción Científica
OAI Identifier:oai:fisabio.fundanetsuite.com:p18349
Acesso em linha:https://fisabio.portalinvestigacion.com/publicaciones/18349
Access Level:acceso abierto
Palavra-chave:vericiguat
worsening heart failure
guideline-directed medical therapy
VERISEC registry
heart failure reduced ejection fraction
id ES_95bd01fdf46c4676c78d75ec0ff4faa7
oai_identifier_str oai:fisabio.fundanetsuite.com:p18349
network_acronym_str ES
network_name_str España
repository_id_str
spelling Clinical profile of an unselected population with heart failure treated with vericiguat in real life: differences with the VICTORIA trialEsteban-Fernández, ARecio-Mayoral, ALópez-Vilella, RDe Lara, GBarrantes-Castillo, MGómez-Otero, INuñez-Villota, JRobles-Gamboa, CLópez-Aguilera, JIniesta-Manjavacas, AFluvió, PPastor-Pérez, FBelarte-Tornero, LAlonso-Salinas, GDíez-Villanueva, PERISEC Registry Researchersvericiguatworsening heart failureguideline-directed medical therapyVERISEC registryheart failure reduced ejection fractionIntroduction Vericiguat, an oral stimulator of soluble guanylate cyclase, reduces cardiovascular mortality and hospitalisations in patients with heart failure (HF) and reduced ejection fraction, as demonstrated in the VICTORIA trial. This study assessed the real-world use of vericiguat.Material and methods This cross-sectional, prospective and multicenter registry (VERISEC) included 776 patients from 43 centres in Spain between December 2022 and October 2023. Of these patients, 79.6% were male, with a mean age of 72.4 (SD:8.7) years. Patients in VERISEC were older and had more comorbidities (diabetes, advanced chronic kidney disease) compared to VICTORIA, with 20% having an estimated glomerular filtration rate below 30 ml/min. They also had higher natriuretic peptide levels [NT-proBNP: 3551 (IQR: 1,675.9, 7,054.0)] pg/ml. Most patients (79.8%) started vericiguat after HF decompensation within the previous three months, with high use of loop diuretics (with an average dose of 65 mg/day) and implanted devices (50%). Sixty percent of patients were on quadruple therapy, with a higher use of sodium-glucose co-transporter 2 inhibitors compared to the VICTORIA trial. Despite the more severe disease in the VERISEC cohort, the implementation of guideline-directed medical therapy was greater than in VICTORIA, although vericiguat was initiated at lower blood pressure levels.Conclusions Patients in the VERISEC registry had more severe illness and higher comorbidities compared to those in the VICTORIA, despite receiving optimised treatments. Further research is needed to identify which patients may benefit the most from vericiguat treatment.FRONTIERS MEDIA SA2025info:eu-repo/semantics/articleinfo:eu-repo/semantics/publishedVersionhttps://fisabio.portalinvestigacion.com/publicaciones/18349Frontiers in Cardiovascular MedicineISSN: 2297055Xreponame:r-FISABIO. Repositorio Institucional de Producción Científicainstname:Fundación para el Fomento de la Investigación Sanitaria y Biomédica de la Comunitat Valenciana (FISABIO)Inglésinfo:eu-repo/semantics/openAccessoai:fisabio.fundanetsuite.com:p183492026-06-11T12:45:17Z
dc.title.none.fl_str_mv Clinical profile of an unselected population with heart failure treated with vericiguat in real life: differences with the VICTORIA trial
title Clinical profile of an unselected population with heart failure treated with vericiguat in real life: differences with the VICTORIA trial
spellingShingle Clinical profile of an unselected population with heart failure treated with vericiguat in real life: differences with the VICTORIA trial
Esteban-Fernández, A
vericiguat
worsening heart failure
guideline-directed medical therapy
VERISEC registry
heart failure reduced ejection fraction
title_short Clinical profile of an unselected population with heart failure treated with vericiguat in real life: differences with the VICTORIA trial
title_full Clinical profile of an unselected population with heart failure treated with vericiguat in real life: differences with the VICTORIA trial
title_fullStr Clinical profile of an unselected population with heart failure treated with vericiguat in real life: differences with the VICTORIA trial
title_full_unstemmed Clinical profile of an unselected population with heart failure treated with vericiguat in real life: differences with the VICTORIA trial
title_sort Clinical profile of an unselected population with heart failure treated with vericiguat in real life: differences with the VICTORIA trial
dc.creator.none.fl_str_mv Esteban-Fernández, A
Recio-Mayoral, A
López-Vilella, R
De Lara, G
Barrantes-Castillo, M
Gómez-Otero, I
Nuñez-Villota, J
Robles-Gamboa, C
López-Aguilera, J
Iniesta-Manjavacas, A
Fluvió, P
Pastor-Pérez, F
Belarte-Tornero, L
Alonso-Salinas, G
Díez-Villanueva, P
ERISEC Registry Researchers
author Esteban-Fernández, A
author_facet Esteban-Fernández, A
Recio-Mayoral, A
López-Vilella, R
De Lara, G
Barrantes-Castillo, M
Gómez-Otero, I
Nuñez-Villota, J
Robles-Gamboa, C
López-Aguilera, J
Iniesta-Manjavacas, A
Fluvió, P
Pastor-Pérez, F
Belarte-Tornero, L
Alonso-Salinas, G
Díez-Villanueva, P
ERISEC Registry Researchers
author_role author
author2 Recio-Mayoral, A
López-Vilella, R
De Lara, G
Barrantes-Castillo, M
Gómez-Otero, I
Nuñez-Villota, J
Robles-Gamboa, C
López-Aguilera, J
Iniesta-Manjavacas, A
Fluvió, P
Pastor-Pérez, F
Belarte-Tornero, L
Alonso-Salinas, G
Díez-Villanueva, P
ERISEC Registry Researchers
author2_role author
author
author
author
author
author
author
author
author
author
author
author
author
author
author
dc.subject.none.fl_str_mv vericiguat
worsening heart failure
guideline-directed medical therapy
VERISEC registry
heart failure reduced ejection fraction
topic vericiguat
worsening heart failure
guideline-directed medical therapy
VERISEC registry
heart failure reduced ejection fraction
description Introduction Vericiguat, an oral stimulator of soluble guanylate cyclase, reduces cardiovascular mortality and hospitalisations in patients with heart failure (HF) and reduced ejection fraction, as demonstrated in the VICTORIA trial. This study assessed the real-world use of vericiguat.Material and methods This cross-sectional, prospective and multicenter registry (VERISEC) included 776 patients from 43 centres in Spain between December 2022 and October 2023. Of these patients, 79.6% were male, with a mean age of 72.4 (SD:8.7) years. Patients in VERISEC were older and had more comorbidities (diabetes, advanced chronic kidney disease) compared to VICTORIA, with 20% having an estimated glomerular filtration rate below 30 ml/min. They also had higher natriuretic peptide levels [NT-proBNP: 3551 (IQR: 1,675.9, 7,054.0)] pg/ml. Most patients (79.8%) started vericiguat after HF decompensation within the previous three months, with high use of loop diuretics (with an average dose of 65 mg/day) and implanted devices (50%). Sixty percent of patients were on quadruple therapy, with a higher use of sodium-glucose co-transporter 2 inhibitors compared to the VICTORIA trial. Despite the more severe disease in the VERISEC cohort, the implementation of guideline-directed medical therapy was greater than in VICTORIA, although vericiguat was initiated at lower blood pressure levels.Conclusions Patients in the VERISEC registry had more severe illness and higher comorbidities compared to those in the VICTORIA, despite receiving optimised treatments. Further research is needed to identify which patients may benefit the most from vericiguat treatment.
publishDate 2025
dc.date.none.fl_str_mv 2025
dc.type.none.fl_str_mv info:eu-repo/semantics/article
info:eu-repo/semantics/publishedVersion
format article
status_str publishedVersion
dc.identifier.none.fl_str_mv https://fisabio.portalinvestigacion.com/publicaciones/18349
url https://fisabio.portalinvestigacion.com/publicaciones/18349
dc.language.none.fl_str_mv Inglés
language_invalid_str_mv Inglés
dc.rights.none.fl_str_mv info:eu-repo/semantics/openAccess
eu_rights_str_mv openAccess
dc.publisher.none.fl_str_mv FRONTIERS MEDIA SA
publisher.none.fl_str_mv FRONTIERS MEDIA SA
dc.source.none.fl_str_mv Frontiers in Cardiovascular Medicine
ISSN: 2297055X
reponame:r-FISABIO. Repositorio Institucional de Producción Científica
instname:Fundación para el Fomento de la Investigación Sanitaria y Biomédica de la Comunitat Valenciana (FISABIO)
instname_str Fundación para el Fomento de la Investigación Sanitaria y Biomédica de la Comunitat Valenciana (FISABIO)
reponame_str r-FISABIO. Repositorio Institucional de Producción Científica
collection r-FISABIO. Repositorio Institucional de Producción Científica
repository.name.fl_str_mv
repository.mail.fl_str_mv
_version_ 1869413862459047936
score 15.812429

Registos relacionados